海思科：安瑞克芬注射液新适应症获批

Core Viewpoint - The company Haishi Ke (002653) has received a Class 1 innovative drug registration certificate from the National Medical Products Administration for its injection drug Anruikefen (brand name: Sishujing, R&D code: HSK21542), which is indicated for the treatment of moderate to severe itching associated with chronic kidney disease in adult patients undergoing maintenance hemodialysis [1]. Group 1 - The drug Anruikefen has been approved for a new indication related to chronic kidney disease [1]. - The approval highlights the company's ongoing commitment to developing innovative treatments for patients with specific medical needs [1].